Methods are provided for efficient preparation of hydromorphone or hydrocodone by redox isomerization of morphine or codeine allylic alcohols, respectively, using transition metal aminophosphine catalysts formed in situ.

Methods are provided for efficient preparation of hydromorphone or hydrocodone by redox isomerization of morphine or codeine allylic alcohols, respectively, using transition metal aminophosphine catalysts formed in situ.

Disclosed are methods for converting a first morphinan alkaloid compound into a second morphinan alkaloid compound in the presence of a neopinone isomerase enzyme under reaction conditions permitting the conversion of the first alkaloid compound into the second alkaloid compound. The first alkaloid compound can be neopinone or neomorphinone. The second alkaloid compound can be codeinone or morphinone. Related compositions are also disclosed.

The present invention relates to novel 6-acetylmorphine analogs, and methods for their synthesis and use. Such analogs are designed to provide a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.

The present invention relates to novel 6-acetylmorphine analogs, and methods for their synthesis and use. Such analogs are designed to provide a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.

In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.

In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.

Compositions, methods, and kits are disclosed directed at haptens, immunogens and immunoassays for oxycodone and metabolites thereof. The compounds are exemplified by compounds of the Formula I. The method comprises providing in combination in a medium (i) a sample suspected of containing oxycodone and/or oxycodone metabolites, a compound of the Formula I wherein R.sup.4 or R.sup.5 is a label, and an antibody for oxycodone or a metabolite thereof. The medium is examined for the presence of a complex comprising the labeled compound of Formula I where the presence of such as complex indicates the presence of oxycodone or oxycodone metabolite in the sample.

Compounds, compositions, and methods for the treatment or prevention of symptoms, conditions, and diseases that may benefit from NMDAR modulation, including administering a compound of the morphinan family to a subject. The method may include administration of dextromorphine to a subject experiencing a symptom, condition, or disease that may benefit from NMDAR modulation, (except for the indications of pain and addiction), or may include administering dextrocodeine, dextrohydromorphone, dextrohydrocodone, dextrooxymorphone, dextrooxycodone, dextrooripavine, dextrothebaine, dextroethorphine, and dextrobuprenorphine to a subject experiencing a symptom, condition, or disease that may benefit from NMDAR modulation. Derivatives and stereoisomers of such compounds may also be used.

Compounds, compositions, and methods for the treatment or prevention of symptoms, conditions, and diseases that may benefit from NMDAR modulation, including administering a compound of the morphinan family to a subject. The method may include administration of dextromorphine to a subject experiencing a symptom, condition, or disease that may benefit from NMDAR modulation, (except for the indications of pain and addiction), or may include administering dextrocodeine, dextrohydromorphone, dextrohydrocodone, dextrooxymorphone, dextrooxycodone, dextrooripavine, dextrothebaine, dextroethorphine, and dextrobuprenorphine to a subject experiencing a symptom, condition, or disease that may benefit from NMDAR modulation. Derivatives and stereoisomers of such compounds may also be used.